After 72 weeks: Participants taking 6 mg of orforglipron lost an average of 7.5% of their body weight (equivalent to 9 mg of Foundayo) Participants taking 12 mg or 37 mg of orforglipron lost an average of 8.4% and 11.2%, respectively (equivalent to 14.5 mg or 17.2 mg of Foundayo, respectively) Side effects and risks of GLP-1s The most common side effects from these medicines are mild gastrointestinal (GI) issues, such as: Vomiting Diarrhea Abdominal pain Rare but serious side effects of GLP-1s may include: Pancreatitis, or inflammation of the pancreas Gallbladder disease (including gallstones or gallbladder inflammation) Low blood sugar ( hypoglycemia ), particularly in people who also take insulin or certain pills for diabetes Severe allergic reactions Severe gastrointestinal reactions, which may lead to dehydration and related kidney problems Diabetic retinopathy complications in people with this eye disease Risk of pulmonary aspiration ( stomach contents entering the lungs) during surgery in people undergoing deep sedation or anesthesia GLP-1s also carry a boxed warning because they caused thyroid C-cell tumors in studies of rats
Available online at: (accessed August 25, 2025)
Correlation between dietary selenium intake and stroke in the National Health and Nutrition Examination Survey 2003-2018
doi: 10.1136/gutjnl-2019-319766 167 WieremaT
www.ixpertadvisors.com #DCATWeek #Pharma #CDMO #Biotech #PharmaManufacturing #USPharma #iXPERTAdvisors To view or add a comment, sign in In 2026, pharmaceutical manufacturers could be caught between a cliff and a hard place
Take home message As weve covered in this article, there are many reasons why you might not be losing weight on semaglutide
